MDNA113, a novel bifunctional Superkine developed by Medicenna Therapeutics, has demonstrated exceptional selectivity and potency in targeting tumors while maintaining a favorable systemic tolerability profile. Recent preclinical data presented at the AACR Annual Meeting 2026 highlight MDNA113’s superior performance compared to a traditional anti-PD-1 x IL-2α-biased bispecific in non-human primates, where it was well tolerated at doses up to 50 mg/kg, while the comparator exhibited severe toxicity. This promising safety profile supports Medicenna’s plans for an Investigational New Drug (IND) submission anticipated in late 2026.

The significance of MDNA113 lies in its innovative architecture, which combines tumor anchoring and dual conditional activation mechanisms. The design achieves over **10,000-fold attenuation of IL-2R agonism compared to its parent molecule, while preserving full PD-1/PD-L1 blockade. This strategic masking allows for localized IL-2 activation within the tumor microenvironment, leading to enhanced therapeutic efficacy without systemic exposure. In syngeneic mouse models, MDNA113 not only inhibited tumor growth but also preferentially expanded CD8+ T cells, underscoring its potential to improve immunotherapeutic outcomes in patients with advanced solid tumors.**

The implications for the field are substantial, as MDNA113’s unique approach could redefine dosing strategies for PD-1 x IL-2 therapies. By demonstrating a significantly wider therapeutic window, it addresses the safety and efficacy limitations of first-generation bispecifics, potentially accelerating the development timeline for similar agents. This advancement may catalyze further investment and research into tumor-targeted immunotherapies, paving the way for next-generation treatments that enhance patient outcomes in oncology.

Source: globenewswire.com